# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of...
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ: VKTX) with a Buy and maintains $102...
BTIG analyst Justin Zelin reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $125 price target.